Test Price
2,800 AED✅ Home Collection Available
BMPR1A Gene Hereditary Mixed Polyposis Syndrome Type 2 (HMPS2) Genetic Test | 2800 AED | Dubai Healthcare City
Executive Summary & Core Metrics
Executive Summary & Clinical Confidence
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test clinical interpretation of results with a genetic counsellor.
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next Generation Sequencing (NGS) test detects pathogenic variants in the BMPR1A gene associated with Hereditary Mixed Polyposis Syndrome Type 2 (HMPS2). HMPS2 significantly increases the lifetime risk of colorectal cancer, making early genetic identification critical for targeted surveillance and prevention strategies. The analysis covers full gene sequencing including exon, intron boundaries, and copy number variant detection.
| Feature | Our Test (NGS) | Closest Alternative (Single‑Site/Sanger) |
|---|---|---|
| Precision | Full gene sequencing; detects point mutations, indels, and copy number variants | Targeted mutation hot‑spots only; limited CNV detection |
| Methodology | Next Generation Sequencing (Illumina platform) | Sanger sequencing or PCR‑based single exon analysis |
| Turnaround Time | 3–4 Weeks (comprehensive analysis) | 2–4 weeks (limited targets) |
*All times exclude sample transit. Rush processing available on request.
Physician Insight & Safety Protocols
“A positive BMPR1A result opens the door for life‑saving colonoscopic surveillance; a negative result, however, does not erase the family legacy—clinical correlation with a detailed pedigree remains paramount. I urge you to view this test not as a standalone answer, but as a compass that guides personalised prevention. Your story matters, and we are honoured to walk this path with you.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Treatment Continuity
⚠️ Do not discontinue any prescribed medication or alter your treatment plan without direct consultation with your treating physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active chemotherapy or recent blood transfusion (within 2 weeks) that may compromise DNA integrity; inability to provide informed consent; or incomplete pre‑test genetic counselling session.
- Emergency Red Flags: Sudden, severe abdominal pain; rectal bleeding or melena; signs of bowel obstruction (vomiting, distension). If any of these occur, seek immediate emergency medical attention—do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the BMPR1A gene test and why is it done?
Snippet Answer: The BMPR1A NGS test detects inherited mutations in the BMPR1A gene that cause hereditary mixed polyposis syndrome, significantly raising colorectal cancer risk.
It is indicated for individuals with a personal or family history of multiple and/or mixed gastrointestinal polyps, early‑onset colorectal cancer, or a known familial BMPR1A mutation. Early identification enables tailored endoscopic surveillance and risk‑reduction strategies.
2. Who should consider undergoing this genetic test?
Snippet Answer: Anyone with multiple mixed colon polyps, a strong family history of colorectal cancer, or a first‑degree relative with a known BMPR1A mutation should consider testing.
The test is also valuable for at‑risk relatives to clarify their own cancer predisposition and for families seeking peace of mind when a hereditary pattern is suspected.
3. How do I prepare for the test and what can I expect?
Snippet Answer: No fasting is required, but you must complete a pre‑genetic counselling session to document your family history and sign informed consent.
A simple blood sample (or DNA from FTA card) is collected via our home phlebotomy service; results are ready in 3–4 weeks and a genetic counsellor will explain the findings in a follow‑up teleconsultation.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory framework of the Dubai Health Authority (DHA) and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient data is encrypted, access‑controlled, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | BMPR1A Gene Hereditary Mixed Polyposis Syndrome Type 2 (HMPS2) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next Generation Sequencing (Illumina platform) |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 21634-2 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians